Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer

Tools
- Tools
+ Tools

Leong, S. S., Fong, K. W., Lim, W. T., Toh, C. K., Yap, S. P., Hee, Siew Wan and Tan, E. H. (2010) A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer, 67 (3). pp. 325-329. doi:10.1016/j.lungcan.2009.04.022

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/j.lungcan.2009.04.022

Request Changes to record.

Abstract

This is phase II study evaluating a non-platinum-containing regimen, used in conjunction with radiotherapy, in patients with locally advanced non-small cell lung cancer (NSCLC). Patients with non-resectable stage III NSCLC were treated with two cycles of induction gemcitabine (1000 mg/m2) and vinorelbine (25 mg/m2) given on D1,8 every 21 days, followed by thoracic radiotherapy (60–66 Gy) with concurrent weekly vinorelbine (15 mg/m2). The primary objective was to assess response rate and secondary objectives to assess tolerability and to determine the progression-free survival (PFS) and overall survival (OS). Of the 42 patients enrolled on the study, 15 (36%) achieved a partial response (PR) after induction chemotherapy. After chemo-radiotherapy, five patients had complete response (CR) and 19 patients had PR, giving an overall response rate of 52%. The median PFS was 8 months and median OS was 17 months. The regimen was tolerable, with a 21% grade 3/4 neutropenia rate and 38% grade 2/3 esophagitis rate.

Item Type: Journal Article
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences > Statistics and Epidemiology
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Lung Cancer
Publisher: Elsevier
ISSN: 5002
Official Date: 2010
Dates:
DateEvent
2010Published
Volume: 67
Number: 3
Page Range: pp. 325-329
DOI: 10.1016/j.lungcan.2009.04.022
Status: Peer Reviewed
Publication Status: Published
Publisher Statement: Cited By :3 Export Date: 5 March 2015
Access rights to Published version: Restricted or Subscription Access
Related URLs:
  • Other

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us